Inclusion Criteria:

• 1. T2D according to American Diabetes Association (ADA) criteria (38).
• 2. Age ≥ 18 yr.
• 3. HbA1c \< 9.5%.
• 4. Presence of DPN based on Michigan Neuropathy Screening Instrument (combined questionnaire and a clinical examination of the response to vibration perception examination using a 128 Hz tuning fork and ankle reflexes), a validated, sensitive, and specific instrument for the diagnosis of DPN as reported (39,40). Pin prick sensation will be performed (as measures of small-fiber neuropathy) for DPN confirmation (41-43).
• 5. Be willing and capable of providing a written consent form and willing and able to cooperate with the medical procedures for the study duration.
• 6. Women of childbearing potential must be willing to use appropriate contraception during the entire trial.

Exclusion Criteria:

• 1. History of any other causes of neuropathy (e.g. other neurological disorders, medications-induced, occupational history, active hepatitis C infection, exposure to toxins).
• 2. History of persistent macroalbuminuria \[random urine microalbumin creatinine ratio (ACR) up to 300 mg/gm\]is acceptable if calculated GFR is \>60 (16).
• 3. Serum creatinine \>1.4 for women and \>1.5 for men or eGFR \<60 \[calculated using the CKD-EPI equation\].
• 4. Use of warfarin (Coumadin), clopidogrel (Plavix), dipyridamole (Persantine), heparin or other anticoagulants, probenecid (Benemid, Probalan), sulfinpyrazone (Anturane) or other uricosuric agents; Participants must agree to not use high-dose aspirin during the course of the study. Daily low-dose aspirin treatment (not more than 81 mg per day) may be continued if currently prescribed.
• 5. Uncontrolled hypertension
• 6. Triglyceride \> 400 mg/100ml.
• 7. History of previous organ transplantation (kidney, pancreas, liver, lung or cardiac transplantation).
• 8. History of drug or alcohol abuse within 5 years, or current weekly alcohol consumption \>10 units/week.
• 9. Pregnancy or lactation or desire to become pregnant in the next 12 months
• 10. Requiring long-term glucocorticoid therapy or chronic immunosuppressive therapy: inhaled steroid use for management of asthma is not an absolute exclusion. .
• 11. Participation in an experimental medication trial within 3 months of starting the study.
• 12. Current therapy for malignant disease other than basal cell or squamous cell skin cancer.
• 13. History of gastrointestinal bleeding or active gastric ulcer;
• 14. Screening laboratory abnormalities including AST (SGOT) and or ALT (SGPT) \> 2.5 x the upper limit of normal (ULN), total bilirubin \> 1.5 x ULN, platelets \< 100,000;
• 15. History of taking fish oil supplements in the 6 months prior to the screening visit.
• 16. History of fish or shellfish allergy.
• 17. Presence of any condition that in the opinion of the investigators would make it unlikely for the participant to complete study.
• 18. Known hypersensitivity to salsalate or inactive ingredients. Patients who have experienced asthma, hives, or other allergic-type reactions to aspirin or other NSAIDs are excluded from participation.
• 19. Use of lithium.
• 20. Absent one or both great toes.